Relmada Therapeutics to Present at Leerink Partners Conference

Biotech company to showcase its pipeline of oncology and CNS therapies

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Relmada Therapeutics, a clinical-stage biotech company focused on developing treatments for oncology and central nervous system disorders, announced that its CEO and CFO will participate in the upcoming Leerink Partners Global Healthcare Conference in Miami, Florida. The company will present in a fireside chat format and also be available for one-on-one investor meetings during the 3-day event.

Why it matters

Relmada's lead drug candidates, NDV-01 and sepranolone, are in mid-stage clinical trials, indicating the company's pipeline has advanced significantly. Participation in high-profile healthcare conferences like Leerink Partners provides Relmada an opportunity to showcase its progress and engage with potential investors as it seeks to fund further development.

The details

Relmada's CEO Sergio Traversa and CFO Maged Shenouda will represent the company at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET. The presentation will be in a fireside chat format, and the executives will also be available for one-on-one investor meetings throughout the 3-day event.

  • The Leerink Partners Global Healthcare Conference will be held from March 8-11, 2026 in Miami, Florida.
  • Relmada's fireside chat presentation is scheduled for Tuesday, March 10, 2026 at 8:40 AM ET.

The players

Relmada Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions.

Sergio Traversa

Chief Executive Officer of Relmada Therapeutics.

Maged Shenouda

Chief Financial Officer of Relmada Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

Relmada's participation in the Leerink Partners Global Healthcare Conference demonstrates the company's progress in advancing its pipeline of oncology and central nervous system therapies. As Relmada seeks to fund further development, engaging with potential investors at high-profile industry events will be crucial to the company's growth strategy.